High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 105-109

  Yusof, Wardah ^a   Gan, Siew Hua ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

CYP2A6; Genetic polymorphism; Nested PCR

Indexed keywords

ARTESUNATE; CYTOCHROME P450 2A6; GENOMIC DNA;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA FLANKING REGION; DNA ISOLATION; EXON; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; HUMAN; HUMAN EXPERIMENT; MALAYSIA; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TATA BOX;

ALLELES; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG TOXICITY; GENE FREQUENCY; GENOTYPE; HUMANS; MALAYSIA; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ARTESUNATE;

EID: 64849115268     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.01.032     Document Type: Article

References (25)

1. Taavitsainen P, Cytochrome P450 Isoform-specific In Vitro Methods To Predict Drug Metabolism And Interactions. Academic Dissertation. University of Oulu. 2001.
2. Nelson D.R., Koymans L., Kamataki T., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
3. Frye R.F. Probing the world of cytochrome P450 enzymes. Mol Interv 4 (2004) 157-162
4. Walsky R.L., and Obach R.S. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 647-660
5. Fukami T., Nakajima M., Higashi E., et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 33 (2005) 1202-1210
6. Oscarson M., McLellan R.A., Gullsten H., et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460 (1999) 321-327
7. Asimus S., Hai T.N., Huong N.V., and Ashton M. Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol (2007) 10.1007/s00228-007-0406-1
8. Kiyotani K., Yamazaki H., Fujieda, et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6* 9). Pharmacogenetics 13 (2003) 689-695
9. Pitarque M., Rodriguez-Antona C., Oscarson M., and Ingelman-Sundberg M. Transcriptional regulation of the human CYP2A6 gene. J Pharmacol Exp Ther 313 (2005) 814-822
10. Yamano S., Tatsuno J., and Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29 (1990) 1322-1329
11. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., and Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284 (2001) 455-460
12. Oscarson M., McLellan R.A., Gullsteèn H., et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448 (1999) 105-110
13. Oscarson M., Gullsten H., Rautio A., et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438 (1998) 201-205
14. Kwon J.T., Nakajima M., Chai S., et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 11 (2001) 317-323
15. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., and Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74 (2003) 69-76
16. Nurfadhlina M., Foong K., Teh L.K., Tan S.C., Mohd Zaki S., and Ismail R. CYP2A6 polymorphisms in Malays, Chinese and Indians. Xenobiotica 36 8 (2006) 684-692
17. Adjuik M., Agnamey P., and Babiker A. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359 (2002) 1365-1372
18. World Health Organization (WHO). Malaria-Disease Burden in SEA Region (2008). http://www.searo.who.int/EN/Section10/Section21/Section340_4018.htm http://www.searo.who.int/EN/Section10/Section21/Section340_4018.htm 24 September 2008.
19. Vasconcelos G.M., Struchiner C.J., and Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. The Pharmacogenomics Journal 5 (2005) 42-48
20. Schoedel K., Hoffmann E., Rao Y., Sellers E., and Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14 (2004) 615-626
21. Yoshida R., Nakajima M., Watanabe Y., Kwon J.T., and Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54 (2002) 511-517
22. Fernandez-Salguero P.M.G., Hoffman S., Cholerton S., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57 (1995) 651-660
23. Peamkrasatam S., Sriwatanakul K., Kiyotani K., et al. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 21 (2006) 475-484
24. Xu C., Rao Y.S., Xu B., et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 290 (2002) 318-324
25. Nakajima M., Yoshida R., Fukami T., McLeod H., and Yokoi T. Novel human CYP2A6 alleles confound gene deletion analysis. FEBBS Letters 569 (2004) 75-81